Why the study?
Does a pharmacogenetic dosing algorithm improve cost-effectiveness compared to a clinical dosing algorithm for coumarin anticoagulants in The Netherlands?
Does a pharmacogenetic dosing algorithm improve cost-effectiveness compared to a clinical dosing algorithm for coumarin anticoagulants in The Netherlands?
Pharmacogenetic dosing for coumarin anticoagulants provides minimal health benefits and is not cost-effective at current genotyping costs in the Netherlands.
Does not support routine pharmacogenetic dosing for coumarins in the Netherlands; leaves open whether lower genotyping costs could change cost-effectiveness.
AIM: To investigate the cost-effectiveness of a pharmacogenetic dosing algorithm versus a clinical dosing algorithm for coumarin anticoagulants in The Netherlands. MATERIALS & METHODS: A decision-analytic Markov model was used to analyze the cost-effectiveness of pharmacogenetic dosing of phenprocoumon and acenocoumarol versus clinical dosing. RESULTS: Pharmacogenetic dosing increased costs by €33 and quality-adjusted life-years (QALYs) by 0.001. The incremental cost-effectiveness ratios were €28,349 and €24,427 per QALY gained for phenprocoumon and acenocoumarol, respectively. At a willingness-to-pay threshold of €20,000 per QALY, the pharmacogenetic dosing algorithm was not likely to be cost effective compared with the clinical dosing algorithm. CONCLUSION: Pharmacogenetic dosing improves health only slightly when compared with clinical dosing. However, availability of low-cost genotyping would make it a cost-effective option.
No takes yet. Share an insight, caveat, or question.
Verhoef et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: